We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eiger BioPharmaceuticals Inc | NASDAQ:EIGR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.725 | 1.72 | 1.73 | 0 | 01:00:00 |
From May 2023 to May 2024
By Sabela Ojea
Eiger BioPharmaceuticals said it is discontinuing the company's phase 3 study to treat peginterferon lambda in patients with chronic hepatitis delta and has ceased active discussions for a worldwide license of the treatment.
The commercial-stage biopharmaceutical company said its decision is based on the Data Safety Monitoring Board, which recommended the discontinuation following a quarterly safety review.
Four patients with hepatobiliary events resulted in liver decompensation during the LIMT-2 study, the company said.
"We will work closely with the Food and Drug Administration and our investigators to conduct an orderly termination of the LIMT-2 study in the interest of patient safety," Chief Executive David Apelian added.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 12, 2023 17:02 ET (21:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Eiger BioPharmaceuticals Chart |
1 Month Eiger BioPharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
